Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « AbsEn.i » - entrée « cov »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
courses < cov < cov d  Facettes :

List of bibliographic references indexed by cov

Number of relevant bibliographic references: 838.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000007 (2021) Natalia Sasoni [Argentine] ; Milton Rodriguez Müller [Argentine] ; Graciela Posse [Argentine] ; Jorge González [Argentine] ; Florencia Leonardelli [Argentine] ; Guillermo Garcia-Effron [Argentine]SARS-CoV-2 and Aspergillus section Fumigati coinfection in an immunocompetent patient treated with corticosteroids.
000009 (2021) Rashed Noor [Bangladesh]Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.
000010 (2021) Nicole Fagan [Irlande (pays)] ; Nekma Meah [Australie] ; Katherine York [Afrique du Sud] ; Laita Bokhari [Australie] ; Godfrey Fletcher [Irlande (pays)] ; Gang Chen [Australie] ; Desmond J. Tobin [Irlande (pays)] ; Andrew Messenger [Royaume-Uni] ; Alan D. Irvine [Irlande (pays)] ; Rodney Sinclair [Australie] ; Dmitri Wall [Irlande (pays)]Shedding light on therapeutics in alopecia and their relevance to COVID-19.
000015 (2021) Roberto Ariel Abelda O Zu Iga [Mexique] ; Silvia Mercedes Coca [Mexique] ; Giuliana Florencia Abelda O [Mexique] ; Ruth Ana María González-Villoria [Mexique]Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.
000022 (2021) E. Díaz [Espagne] ; R. Amézaga Menéndez [Espagne] ; P. Vidal Cortés [Espagne] ; M G Escapa [Espagne] ; B. Suberviola [Espagne] ; A. Serrano Lázaro [Espagne] ; P. Marcos Neira [Espagne] ; M. Quintana Díaz [Espagne] ; M. Catalán González [Espagne][Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
000031 (2021) Hülya Gamze Çelik [Turquie] ; Iran Keske [Turquie] ; Ülker Ener [Turquie] ; Müge Tekba [Turquie] ; Mahir Kapmaz [Turquie] ; Krü Taylan Ahin [Turquie] ; Asl Özy Ld R M [Turquie] ; Saide Aytekin [Turquie] ; Vedat Aytekin [Turquie] ; Önder Ergönül [Turquie]Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
000033 (2021) Dania Altulea [Pays-Bas] ; Sjors Maassen [Pays-Bas] ; Maksim V. Baranov [Pays-Bas] ; Geert Van Den Bogaart [Pays-Bas]What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
000035 (2021) L. Anedda [Italie] ; L. Bianchini ; L. Cuzzolin ; G. Finco ; V. Fanos ; M A MarcialisWhat if COVID-19 affects the child: which weapons and how to use them.
000037 (2021) Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne]What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
000038 (2021) María Antonela Zígolo [Argentine] ; Matías Rivero Goytia [Argentine] ; Hugo Ramiro Poma [Argentine] ; Ver Nica Beatriz Rajal [Singapour] ; Ver Nica Patricia Irazusta [Argentine]Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.
000039 (2021) Roland Duculan ; Deanna Jannat-Khah ; Bella Mehta ; Lisa A. Mandl ; Medha Barbhaiya ; Anne R. Bass ; Carol A. MancusoVariables Associated With Perceived Risk of Contracting SARS-CoV-2 Infection During the COVID-19 Pandemic Among Patients With Systemic Rheumatic Diseases.
000052 (2021) Santanu Santra [Inde] ; Santanab Giri [Inde] ; Madhurima Jana [Inde]Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium.
000053 (2021) Andrew C. Berry [États-Unis] ; Russell S. Gonnering [États-Unis] ; Ivan Rodriguez [États-Unis] ; Qianying Zhang [États-Unis] ; Bruce B. Berry [États-Unis]Unfavorable hydroxychloroquine COVID-19 research associated with authors having a history of political party donations.
000055 (2021) Tuan V. Nguyen [Australie]Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
000058 (2021) George N. Ioannou [États-Unis] ; Ann M. O'Hare [États-Unis] ; Kristin Berry [États-Unis] ; Vincent S. Fan [États-Unis] ; Kristina Crothers [États-Unis] ; Mckenna C. Eastment [États-Unis] ; Emily Locke [États-Unis] ; Pamela Green [États-Unis] ; Javeed A. Shah [États-Unis] ; Jason A. Dominitz [États-Unis]Trends over time in the risk of adverse outcomes among patients with SARS-CoV-2 infection.
000062 (2021) Mohamed A. Taha [États-Unis, Égypte] ; Christian A. Hall [États-Unis] ; Colin J. Shortess [États-Unis] ; Richard F. Rathbone [États-Unis] ; Henry P. Barham [États-Unis]Treatment Protocol for COVID-19 Based on T2R Phenotype.
000065 (2021) Guobing Li [République populaire de Chine, États-Unis] ; Shasha Ruan [République populaire de Chine] ; Xiaolu Zhao [République populaire de Chine] ; Qi Liu [États-Unis] ; Yali Dou [États-Unis] ; Fengbiao Mao [République populaire de Chine]Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.
000069 (2021) Waqas Aslam [Oman] ; Carla R. Lamb [États-Unis] ; Nadia Ali [États-Unis]Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
000072 (2021) Konstantinos Parperis [Chypre (pays), États-Unis]To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
000075 (2021) Sawsan Elgohary [Égypte] ; Aya A. Elkhodiry [Égypte] ; Nada S. Amin [Égypte] ; Ulrike Stein [Allemagne] ; Hend M. El Tayebi [Égypte]Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?
000086 (2021) Gerard Espinosa [Espagne] ; Sergio Prieto-González [Espagne] ; Mireia Llevadot [Espagne] ; Javier Marco-Hernández [Espagne] ; Antonio Martínez-Artu A [Espagne] ; Albert Pérez-Isidro [Espagne] ; Elia Rifé [Espagne] ; Ricard Cervera [Espagne]The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "cov" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "cov" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    cov
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021